Sanofi agrees to settle thousands of ZantacZantac cancer claims
05 Apr 2024
Patent Infringement
Sanofi confirmed to FirstWord on Friday that it reached a deal in principle to settle approximately 4000 personal injury lawsuits accusing the company of selling the now-discontinued heartburn medicine Zantac (ranitidine) without warning patients that it could potentially cause cancer.
The settlement, which marks the first major resolution of cases related to the product, will apply to litigation pending in courts in US states other than Delaware.
"Sanofi has vigorously defended the Zantac litigation since the outset and will continue to do so," said a Sanofi spokesperson. "Consistent with the federal court's ruling that plaintiffs had insufficient evidence that ranitidine can cause plaintiffs' alleged cancers, the medical, scientific, and regulatory communities have extensively evaluated and have found the allegations of the plaintiffs that Zantac causes cancer to be without merit."
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.